Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2086]

Best practice in precision medicine for prostate cancer

Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich

Best practice in precision medicine for prostate cancer ( Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich )

ctDNA-guided adjuvant atezolizumab improves OS in MIBC

Prof Thomas Powles - Barts Cancer Institute, London, UK

ctDNA-guided adjuvant atezolizumab improves OS in MIBC ( Prof Thomas Powles - Barts Cancer Institute, London, UK )

ctDNA-guided adjuvant chemo de-escalation reduces toxicity with comparable...

Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia

ctDNA-guided adjuvant chemo de-escalation reduces toxicity with comparable outcomes in stage III colon cancer ( Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia )

Circulating tumour DNA a useful marker in CRC treatment efficacy, but only...

Dr Emerik Österlund - MD Anderson Cancer Center, Houston, USA

Circulating tumour DNA a useful marker in CRC treatment efficacy, but only alongside others ( Dr Emerik Österlund - MD Anderson Cancer Center, Houston, USA )

Key insights from lung cancer research at ASCO 2025

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Key insights from lung cancer research at ASCO 2025 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

ASCO 2025: Latest updates in mRCC

Dr Michael Serzan, Dr Guillermo De Velasco, Dr Alessandro Rametta and Dr Javier...

ASCO 2025: Latest updates in mRCC ( Dr Michael Serzan, Dr Guillermo De Velasco, Dr Alessandro Rametta and Dr Javier Puente )

HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC

Dr David Braun - Yale School of Medicine, New Haven, USA

HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC ( Dr David Braun - Yale School of Medicine, New Haven, USA )

Tumour microenvironment and circulating biomarkers predict response to...

Dr David Braun - Yale School of Medicine, New Haven, USA

Tumour microenvironment and circulating biomarkers predict response to immunotherapy in advanced RCC ( Dr David Braun - Yale School of Medicine, New Haven, USA )

New MOAs in prostate cancer treatment - what’s next?

Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini

New MOAs in prostate cancer treatment - what’s next? ( Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini )

Social determinants and survival outcomes in early-onset colorectal cancer in...

Dr Jessica Paulus - Ontada, Boston, USA

Social determinants and survival outcomes in early-onset colorectal cancer in the US ( Dr Jessica Paulus - Ontada, Boston, USA )

Low frequency of dihydropyrimidine dehydrogenase variants in Mexican GI cancers...

Dr Enrique Soto Pérez de Celis - University of Colorado Cancer Center, Aurora...

Low frequency of dihydropyrimidine dehydrogenase variants in Mexican GI cancers should induce testing guideline reform ( Dr Enrique Soto Pérez de Celis - University of Colorado Cancer Center, Aurora, USA )

Molecular assay may help identify NSCLC patients who could benefit from...

Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA

Molecular assay may help identify NSCLC patients who could benefit from adjuvant chemotherapy ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )

More from ecancer